维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

19篇 您的检索式：作者名="Achkar JM"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Treatment of B-lymphoproliferative disorder with a monoclonal anti-interlenkin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial显示文摘	Haddad E Paezesny S Leblond V Seigneurin JM Stern M Achkar A	2001	Blood2001，97，6：	1
	2	Antibody responses to my- cobacterial antigens in children with tuberculosis: chal- lenges and potential diagnostic value显示文摘	Achkar JM Ziegenbalg A	2012	Clin Vaccine Immunol2012，19，12：	1
	3	Candida infections of the genitourinary tract 显示文摘	Achkar JM Fries BC	2010	Clin Mierobiol Rev2010，23，2：	1
	4	Candida infections of the genitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	5	Combined use of serum and urinary antibody for diagnosis of tuberculosis显示文摘	Singh KK Dong Y Hinds L Keen MA Belisle JT ZollaPazner S Achkar JM Nadas AJ Arora VK Laal S	2003	Jinfect Dis2003，188，3：	1
	6	Candida infections of the genitourinary traet显示文摘	Achkar JM Fries BC	2010	Clin Mierobiol Rev2010，23，2：	1
	7	Immunological options for the treatment of tuberculosis:evaluation of novel therapeutic approaches显示文摘	Achkar JM Casadevall A Glatman-Freedman A	2007	Expert Rev Anti Infect Ther2007，5，3：	1
	8	Candida infections of the genitouri- nary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	9	Candida infections of the genitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	10	Candida infections of the genitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	11	Candida infections of the genitourinary tract 显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	12	Candida infections of the genitourinary tract 显示文摘	Achkar JM Fries BC	2010	Clin Microbial Rev2010，23，2：	1
	13	Candida infections of the genitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	14	Mycobacterium tuberculosis malate synthase-and MPT51-based serodiagnostic assay as an adjunct to rapid identification of pulmonary tuberculosis显示文摘	Achkar JM Dong YX Holzman RS	2006	Clin Vaccine Immunol2006，13，11：	1
	15	Candida infections of the genitourinary tract 显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	16	Candida infections of thegenitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	17	Mycobacterium tuberculosis malate synthaseand MPT51-based serodiagnostic assay as an adjunct to rapid identification of pulmonary tuberculasis显示文摘	Achkar JM Dong Y Holzman RS	2006	Clin Vaccine Immunol2006，13，11：	1
	18	Candida infections of the genitourinary tract显示文摘	Achkar JM Fries BC	2010	Clin Microbiol Rev2010，23，2：	1
	19	Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome显示文摘BACKGROUND Individuals with Lynch syndrome(LS)and hereditary non-polyposis colorectal cancer(HNPCC)are at increased risk of both colorectal cancer and other cancers.The interplay between immunosuppression,a comorbid inflammatory condition(CID),and HNPCC on cancer risk is unclear.AIM To evaluate the impact of CIDs,and exposure to monoclonal antibodies and immunomodulators,on cancer risk in individuals with HNPCC.METHODS Individuals prospectively followed in a hereditary cancer registry with LS/HNPCC with the diagnosis of inflammatory bowel disease or rheumatic disease were identified.We compared the proportion of patients with cancer in LS/HNPCC group with and without a CID.We also compared the proportion of patients who developed cancer following a CID diagnosis based upon exposure to immunosuppressive medications.RESULTS A total of 21 patients with LS/HNPCC and a CID were compared to 43 patients with LS/HNPCC but no CID.Cancer occurred in 84.2% with a CID compared to 76.7% without a CID(P=0.74)with no difference in age at first cancer diagnosis 45.5±14.6 vs 43.8±7.1 years(P=0.67).LS specific cancers were diagnosed in 52.4% with a CID vs 44.2% without a CID(P=0.54).Nine of 21(42.9%)patients were exposed to biologics or immunomodulators for the treatment of their CID.Cancer after diagnosis of CID was seen in 7(77.8%)of exposed individuals vs 5(41.7%)individuals unexposed to biologics/immunomodulators(P=0.18).All 7 exposed compared to 3/5 unexposed developed a LS specific cancer.The exposed and unexposed groups were followed for a median 10 years and 8.5 years,respectively.The hazard ratio for cancer with medication exposure was 1.59(P=0.43,95%CI:0.5-5.1).CONCLUSION In patients with LS/HNPCC,the presence of a concurrent inflammatory condition,or use of immunosuppressive medication to treat the inflammatory condition,might not increase the rate of cancer occurrence in this limited study.	Muhammad S Faisal Carol A Burke David Liska Amy L Lightner Brandie Leach Margaret O’Malley Lisa LaGuardia Benjamin Click JP Achkar Matthew Kalady JM Church Gautam Mankaney	2022	World Journal of Clinical Oncology2022，13，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费